Screening and treating H. pylori to prevent gastric cancer in young adults
Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults
This study is testing if screening and treating young adults for H. pylori can help prevent gastric cancer in people aged 30-34 in several European countries.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6800 (estimated) |
| Ages | 30 Years to 34 Years |
| Sex | All |
| Sponsor | University of Latvia Academic / other |
| Locations | 7 sites (Zagreb, City of Zagreb and 6 other locations) |
| Trial ID | NCT06275204 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the feasibility and effectiveness of a population-based H. pylori test-and-treat strategy for preventing gastric cancer among young adults aged 30-34 in several European countries. It will involve testing 6,800 participants for H. pylori infection and assessing the acceptance and outcomes of various eradication therapies. The findings could inform the establishment of a national program for gastric cancer prevention, potentially reducing the incidence and burden of the disease in the long term.
Who should consider this trial
Good fit: Ideal candidates for this study are young adults aged 30-34 who have not previously been treated for H. pylori infection.
Not a fit: Patients with mental or developmental limitations, a history of gastric resection, or those who have previously been treated for H. pylori infection may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of gastric cancer in young adults through early detection and treatment of H. pylori infection.
How similar studies have performed: While this specific approach is novel in Europe, similar strategies have shown promise in other regions for reducing gastric cancer incidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Young adults (generally 30 - 34 years of age) Exclusion Criteria: * Patients with mental or developmental limitations who cannot provide a fully-informed consent to participate (based on the assessment from research or patient's personal physician team) * Previously treated H. pylori infection * History of partial or total gastric resection due to benign or malign lesions
Where this trial is running
Zagreb, City of Zagreb and 6 other locations
- University Hospital Centre Zagreb — Zagreb, City of Zagreb, Croatia (Recruiting)
- Clinical Hospital Center Rijeka — Rijeka, Croatia (Recruiting)
- Beacon Hospital — Dublin, Ireland (Recruiting)
- Clinical and Preventive Medicine of the University of Latvia — Riga, Latvia (Not_yet_recruiting)
- Wroclaw Medical University — Wroclaw, Poland (Recruiting)
- Iuliu Hatieganu University of Medicine and Pharmacy — Cluj-Napoca, Cluj, Romania (Recruiting)
- National Institute of Public Health, Slovenia — Ljubljana, Slovenia (Recruiting)
Study contacts
- Study coordinator: Principal Investigator of the Study - Bojan Tepeš (National Institute of Public Health, Slovenia), Prof., MD
- Email: bojan.tepes@siol.net
- Phone: 0038641325916
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.